Megagen 2025 Annual Report: Operating Profit Doubles to 58.1 Billion KRW

Image Source: MegaGen 2025 Annual Business Report

Operating Profit Doubles to 58.1 Billion KRW / Net Profit Grows 42.6% / Revenue Slightly Declines by 7.89%

DentalGoodNews | March 31, 2026 – South Korea's leading dental implant company, MegaGen Implant, officially released its 2025 Annual Business Report. The report shows that MegaGen achieved annual revenue of 280.736 billion KRW (approximately 1.268 billion RMB), a decrease of 7.89% compared to 304.776 billion KRW (approximately 1.376 billion RMB) in 2024. Despite the contraction in revenue scale, its profitability was outstanding. The annual operating profit reached 58.097 billion KRW (approximately 262 million RMB), a significant increase of 102.1% compared to 28.748 billion KRW (approximately 130 million RMB) in the same period last year.

From a profitability perspective, the company achieved a current net profit of 43.2 billion KRW (approximately 195 million RMB) in 2025, a year-on-year increase of approximately +42%. The growth on the profit side is primarily attributed to effective cost control and optimization of the product portfolio. Against the backdrop of intensified industry competition and global macroeconomic fluctuations, MegaGen has gradually transitioned from scale expansion to quality and efficiency by increasing the sales proportion of high-margin products.

Image Source: MegaGen 2025 Annual Business Report

In terms of business structure, dental implants and related products (Fixture, Abutment) remain the core revenue pillars, with product sales revenue reaching 216.713 billion KRW (approximately 979 million RMB), accounting for about 77.2% of the total. Additionally, sales of equipment such as dental chairs (N2, N3 series) also contributed a significant share. According to public information, MegaGen's export value accounted for 68% of its total revenue in 2025. It has maintained the top position in exports to Europe among South Korean dental companies for 13 consecutive years and remains competitive in the US market.

Regarding investments and mergers & acquisitions, 2025 was the first full fiscal year for MegaGen's integration of BIOLASE. According to previous reports by DGN, MegaGen completed the asset acquisition of the US dental laser giant BIOLASE for $20.5 million in November 2024. The financial report indicates that this M&A integration has enhanced MegaGen's channel coverage capability in the North American market, and the synergistic effects between laser therapy equipment and implant systems are beginning to show. The company plans to revitalize its influence in the laser therapy market through deeper integration.

In recent developments, MegaGen continues to focus on digital clinical solutions. At the Dental South China International Expo held in March 2026, MegaGen showcased its latest "Accelerated Loading Solution." The company disclosed to DGN that this solution allows entry into the loading phase approximately four weeks after implant placement. Furthermore, the promotion of full-arch digital and immediate implant solutions for the molar region also supports its penetration into the high-end market.

As of the end of 2025, MegaGen's total assets amounted to 452.349 billion KRW (approximately 2.043 billion RMB), with total liabilities of 209.063 billion KRW (approximately 944 million RMB), resulting in an asset-liability ratio of approximately 46.2%. The company will continue to deepen the global deployment of its R2 digital solutions, aiming to create value for clinics by enhancing clinical efficiency.